Oral SemaglutideNovo NordiskInsurance Coverage Outlook

Formulary Tier: Diabetes (Rybelsus)

Tier 3 (Preferred Brand) on most commercial plans. Copays typically $70-$150/month. Copay card available: as low as $10/month ($300 max savings per fill, 48 months).

Formulary Tier: Weight Loss (25mg - Predicted)

Expected Tier 4 (Specialty Tier) following Wegovy patterns. Higher copays expected ($150-$300+/month). Manufacturer savings programs expected but not yet announced.

Prior Authorization: Diabetes

~70% of plans require PA with A1C ≥7%, documented metformin failure, and no contraindications. Most employer and ACA plans must decide a PA within 15 days (72 hours if urgent); many decide sooner.

Prior Authorization: Weight Loss (Predicted)

PA expected on plans that cover it with BMI ≥30 (or ≥27 with comorbidity), 6-12 months lifestyle interventions documented, behavioral counseling participation.

Step Therapy

Diabetes: Most plans require metformin failure first.
Weight Loss (Predicted): May require trying phentermine or other lower-cost options before GLP-1 approval. Can delay access 3-6 months.

Diabetes (Rybelsus) - COVERED

95% of Part D Plans cover Rybelsus for type 2 diabetes. Typically Tier 3 with ~90% requiring prior authorization (A1C ≥7%, metformin failure). 2026 out-of-pocket cap: $2,100 annually (Inflation Reduction Act). Copays vary by plan and coverage phase.

Weight Loss (25mg) - BRIDGE ONLY

Part D Exclusion, With a Bridge
By law (Medicare Prescription Drug, Improvement, and Modernization Act of 2003), basic Part D coverage excludes drugs used for weight loss. The Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027) covers the Wegovy pill for weight loss for $50 per monthly fill if you meet CMS's criteria: Age 18+ and BMI ≥35; or BMI ≥30 with HFpEF, uncontrolled high blood pressure or CKD stage 3a+; or BMI ≥27 with prediabetes, a prior heart attack or stroke, or symptomatic PAD. Not eligible if you have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH with moderate-to-advanced liver fibrosis (F2–F3), or if your Part D plan paid for a GLP-1 for you at any time in 2026.

Why the Exclusion?

The 2003 law specifically excludes "drugs used for weight loss" from Part D. This means the same drug (semaglutide) is covered for diabetes but NOT for weight loss, despite being FDA-approved for both.

Will This Change?

Congressional bills (e.g., Treat and Reduce Obesity Act) have been proposed to expand Medicare coverage for obesity medications, but none have passed as of 2025. Would require Congressional action to change the law.

Diabetes (Rybelsus) - Most States Cover

Most state Medicaid programs cover Rybelsus for type 2 diabetes with prior authorization (~80% require PA). Typical criteria: A1C ≥7%, metformin failure documented, no contraindications. Check your state's Preferred Drug List (PDL).

Weight Loss (25mg - Very Limited Expected)

Very few states cover GLP-1s for weight loss on Medicaid. Based on current Wegovy patterns, expect minimal coverage unless state policies expand. NC Medicaid reinstated obesity GLP-1 coverage on December 12, 2025; states change often.

States with Weight Loss Coverage (Currently)

13 states (as of January 2026) provided Medicaid coverage for GLP-1s for obesity (per KFF); check your own state. Typically requires BMI ≥30 (or ≥27 with comorbidity), 6-12 months lifestyle interventions, behavioral program participation.

States Without Weight Loss Coverage

Many state Medicaid programs exclude obesity medications entirely, classifying them as "cosmetic" or "lifestyle" drugs. This may change as evidence for long-term health benefits grows, but current coverage is very limited.

How to Check Your State

Action Steps:
1. Visit your state Medicaid website
2. Search for "Preferred Drug List" (PDL) or "Formulary"
3. Look under "Endocrine" or "Diabetes" for Rybelsus
4. Check "Weight Loss" or "Obesity" categories for GLP-1s
5. Review prior authorization criteria for your state

What It Is: Prior authorization requires your doctor to submit clinical documentation to your insurance company before they'll approve coverage. The insurer reviews your medical history, BMI, comorbidities, and prior treatments to determine if the medication is "medically necessary."

Why It Exists: Insurers use PA to control costs and ensure medications are used appropriately. For expensive medications like GLP-1s, PA helps prevent off-label use and ensures patients meet clinical criteria.

How to Overcome:

• Work with your doctor to submit a complete PA form with all required documentation
• Include a detailed letter of medical necessity explaining why orforglipron is appropriate for you
• Document your BMI, weight-related comorbidities, and prior weight-loss attempts
• If denied, appeal immediately with additional supporting evidence
• Consider using Honest Care's appeal service to improve approval chances

What It Is: Step therapy requires you to try and fail less expensive treatments before your insurer will approve oral semaglutide. For diabetes: typically metformin first. For weight loss: may require phentermine or lifestyle programs first.

Why It Exists: Step therapy controls costs by ensuring patients start with lower-cost interventions. If those work, expensive medications aren't needed. If they don't, the insurer has documentation justifying the upgrade.

How to Overcome:

• Document prior treatment failures thoroughly (medications tried, duration, outcomes)
• Request a step therapy exception if you have contraindications to required first-line drugs
• Demonstrate medical urgency (e.g., uncontrolled diabetes with A1C ≥9%, severe obesity with comorbidities)
• For diabetes: Show why oral semaglutide is preferable to injectable alternatives (patient preference, needle phobia)

What It Is: Quantity limits restrict how much medication you can receive per fill (e.g., 30-day supply only, no 90-day fills). This forces more frequent refills and pharmacy visits.

Why It Exists: Insurers use quantity limits to monitor high-cost medication use and reduce waste. For GLP-1s, limits also ensure patients are actively using the medication and attending follow-up visits.

How to Overcome:

• Request a quantity limit override if 30-day supplies are inconvenient or you travel frequently
• Use mail-order or specialty pharmacies that may allow 90-day supplies
• Set up automatic refills to avoid lapses in coverage

What It Is: Some plans completely exclude certain medications from coverage, meaning no amount of appeals or documentation will result in approval. This is becoming more common for weight-loss drugs as costs rise.

Why It Exists: Employers and insurers may exclude entire drug classes (like obesity medications) to control costs, especially if they consider obesity a "lifestyle" condition rather than a medical disease.

How to Overcome:

• Check your plan's formulary to confirm oral semaglutide coverage for your indication (diabetes vs weight loss)
• If weight loss indication is excluded, appeal to your employer's HR department for formulary changes during annual enrollment
• Consider switching plans during open enrollment if your current plan excludes obesity medications
• Explore manufacturer savings programs: Rybelsus copay card for diabetes ($10/month), patient assistance for uninsured
• For weight loss: If you also have prediabetes or cardiovascular risk factors, emphasize those comorbidities in appeals rather than weight loss alone